BACKGROUND: Anecdotal reports suggests that most clinicians treat medications as belonging to a class with regard to all therapeutic indications; this means that the whole 'class' of drugs is considered to possesses a specific therapeutic action. The present article explores the possible existence of a true 'class effect' for agents available for the treatment of bipolar disorder. METHODS: We reviewed the available treatment data from randomized controlled trials (RCTs) and explored 16 'agent class'/'treatment issue' cases for bipolar disorder. Four classes of agents were examined: first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), antiepileptics and antidepressants, with respect to their efficacy on four treatment issues of bipolar disorder (BD) (acute mania, acute bipolar depression, maintenance against mania, maintenance against depression). RESULTS: From the 16 'agent class'/' treatment issue' cases, only 3 possible class effects were detected, and they all concerned acute mania and antipsychotics. Four effect cases have not been adequately studied (FGAs against acute bipolar depression and in maintenance protection from depression, and antidepressants against acute mania and protection from mania) and they all concern treatment cases with a high risk of switching to the opposite pole, thus research in these areas is poor. There is no 'class effect' at all concerning antiepileptics. CONCLUSIONS: The available data suggest that a 'class effect' is the exception rather than the rule in the treatment of BD. However, the possible presence of a 'class effect' concept discourages clinicians from continued scientific training and reading. Focused educational intervention might be necessary to change this attitude.
BACKGROUND: Anecdotal reports suggests that most clinicians treat medications as belonging to a class with regard to all therapeutic indications; this means that the whole 'class' of drugs is considered to possesses a specific therapeutic action. The present article explores the possible existence of a true 'class effect' for agents available for the treatment of bipolar disorder. METHODS: We reviewed the available treatment data from randomized controlled trials (RCTs) and explored 16 'agent class'/'treatment issue' cases for bipolar disorder. Four classes of agents were examined: first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), antiepileptics and antidepressants, with respect to their efficacy on four treatment issues of bipolar disorder (BD) (acute mania, acute bipolar depression, maintenance against mania, maintenance against depression). RESULTS: From the 16 'agent class'/' treatment issue' cases, only 3 possible class effects were detected, and they all concerned acute mania and antipsychotics. Four effect cases have not been adequately studied (FGAs against acute bipolar depression and in maintenance protection from depression, and antidepressants against acute mania and protection from mania) and they all concern treatment cases with a high risk of switching to the opposite pole, thus research in these areas is poor. There is no 'class effect' at all concerning antiepileptics. CONCLUSIONS: The available data suggest that a 'class effect' is the exception rather than the rule in the treatment of BD. However, the possible presence of a 'class effect' concept discourages clinicians from continued scientific training and reading. Focused educational intervention might be necessary to change this attitude.
Authors: M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier Journal: Arch Gen Psychiatry Date: 2000-09
Authors: Eileen Brown; David L Dunner; Susan L McElroy; Paul E Keck; David H Adams; Elisabeth Degenhardt; Mauricio Tohen; John P Houston Journal: Int J Neuropsychopharmacol Date: 2008-12-11 Impact factor: 5.176
Authors: Mauricio Tohen; Charles L Bowden; Anatoly B Smulevich; Richard Bergstrom; Tonya Quinlan; Olawale Osuntokun; Wei V Wang; Heather S Oliff; Ferenc Martenyi; Ludmila A Kryzhanovskaya; Waldemar Greil Journal: Br J Psychiatry Date: 2008-02 Impact factor: 9.319
Authors: Sanjay Dubé; Gary D Tollefson; Michael E Thase; Susan D Briggs; Luann E Van Campen; Michael Case; Mauricio Tohen Journal: Bipolar Disord Date: 2007-09 Impact factor: 6.744
Authors: Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176
Authors: Konstantinos N Fountoulakis; Allan Young; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Pierre Blier; Hans Jurgen Moeller; Siegfried Kasper Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176
Authors: Michele Fornaro; Domenico De Berardis; Giampaolo Perna; Marco Solmi; Nicola Veronese; Laura Orsolini; Elisabetta Filomena Buonaguro; Felice Iasevoli; Cristiano André Köhler; André Ferrer Carvalho; Andrea de Bartolomeis Journal: Biomed Res Int Date: 2017-05-09 Impact factor: 3.411